Background Image

Latest News

Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

14 June 2017

Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

Oxford, UK; San Jose, CA – 13 June 2017 – Oxford BioTherapeutics Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies, has appointed Dr John McHutchison, Executive Vice President, Clinical Research, Gilead Sciences to its Board of Directors.

Dr McHutchison brings almost 20 years of clinical and drug development experience to the Board, most recently in his tenure at Gilead. He is responsible for Gilead’s development programs in liver diseases, haematology and oncology, and inflammatory and respiratory diseases, having previously served as Senior Vice President, Liver Disease Therapeutics. In his six years at Gilead, he has led the organisation in the successful filing of five NDAs and numerous supplemental label updates across multiple therapeutic areas, including the successful curative HCV regimens.

Dr McHutchison also brings to the Board a wealth of experience from prior academic roles at Duke University Medical Centre, North Carolina, USA; Scripps Clinic, San Diego, USA; and the University of Southern California USA. In addition to his roles on multiple review committees and boards, he is a member of numerous societies, including the Association of American Physicians, and the Royal Australasian College of Physicians.

Speaking about his appointment, Dr McHutchison said “I am delighted to be joining OBT at this exciting time. Their portfolio of novel therapeutic targets they are bringing to the clinic has the potential to produce transformative oncology medicines.” Bernd Seizinger, NED Chairman of OBT, commented: “OBT’s progression as a clinical stage oncology company will benefit from Dr McHutchison’s wealth of knowledge in bringing novel treatments to patients. I, together with the Board, am pleased to welcome Dr McHutchison to the team.”